Regeneron Pharmaceuticals Inc (REGN) : Traynor Capital Management reduced its stake in Regeneron Pharmaceuticals Inc by 10.9% during the most recent quarter end. The investment management company now holds a total of 2,535 shares of Regeneron Pharmaceuticals Inc which is valued at $1,025,103 after selling 310 shares in Regeneron Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on Apr 18, 2016.Regeneron Pharmaceuticals Inc makes up approximately 0.80% of Traynor Capital Management’s portfolio.
Regeneron Pharmaceuticals Inc closed down -5.19 points or -1.27% at $404.38 with 8,49,430 shares getting traded on Friday. Post opening the session at $406.61, the shares hit an intraday low of $394.5 and an intraday high of $411.576 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Other Hedge Funds, Including , New York State Teachers Retirement System reduced its stake in REGN by selling 459 shares or 0.32% in the most recent quarter. The Hedge Fund company now holds 141,818 shares of REGN which is valued at $57,348,363. Regeneron Pharmaceuticals Inc makes up approx 0.15% of New York State Teachers Retirement System’s portfolio.Eqis Capital Management reduced its stake in REGN by selling 674 shares or 13.39% in the most recent quarter. The Hedge Fund company now holds 4,358 shares of REGN which is valued at $1,726,378. Regeneron Pharmaceuticals Inc makes up approx 0.12% of Eqis Capital Management’s portfolio. New England Research Management added REGN to its portfolio by purchasing 975 company shares during the most recent quarter which is valued at $386,237. Regeneron Pharmaceuticals Inc makes up approx 0.33% of New England Research Management’s portfolio.
On the company’s financial health, Regeneron Pharmaceuticals Inc reported $2.83 EPS for the quarter, missing the analyst consensus estimate by $ -0.50 based on the information available during the earnings call on Feb 9, 2016. Analyst had a consensus of $3.33. The company had revenue of $1098.00 million for the quarter, compared to analysts expectations of $1171.42 million. The company’s revenue was up 36.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.79 EPS.
Many Wall Street Analysts have commented on Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc was Downgraded by Wells Fargo to ” Market Perform” on Apr 20, 2016. Shares were Reiterated by Sun Trust Rbsn Humphrey on Mar 17, 2016 to “Neutral” and Lowered the Price Target to $ 410 from a previous price target of $450 .Shares were Downgraded by Chardan Capital Markets on Mar 16, 2016 to ” Sell” and Lowered the Price Target to $ 325 from a previous price target of $375 .
Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.